Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…Abstract Number: 2837 • 2019 ACR/ARP Annual Meeting
Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes
Background/Purpose: Persistent hyperuricaemia is a prerequisite for gout. However, only 10% of people with hyperuricaemia develop symptomatic gout, whereas 25-35% have asymptomatic monosodium urate (MSU)…Abstract Number: 234 • 2018 ACR/ARHP Annual Meeting
Population-Based Estimates of Fatigue Prevalence Among Adults Aged >18 Years with and without Arthritis, United States, 2015-2016
Background/Purpose: Fatigue is a common symptom among adults with arthritis and can severely impact quality-of life. This study’s two objectives were to estimate the national…Abstract Number: 354 • 2018 ACR/ARHP Annual Meeting
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Background/Purpose: Immune checkpoint inhibitors (ICIs) have led to improved outcomes in multiple cancers, but they are associated with immune-related adverse events (irAEs), including inflammatory arthritis.…Abstract Number: 433 • 2018 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Rheumatic Diseases: A Systematic Review and Meta-Analysis
Background/Purpose: Obesity increase the incidence of rheumatic diseases (1-3). Bariatric surgery (BS) improve obesity-related comorbidities (4). The aim of our study was to assess currently…Abstract Number: 871 • 2018 ACR/ARHP Annual Meeting
Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
Background/Purpose: Hyperuricaemia (elevated serum urate) is a central risk factor for gout, an acute inflammatory form of arthritis. The balance between the hepatic production of…Abstract Number: 1151 • 2018 ACR/ARHP Annual Meeting
Comparison of Methodologic Approaches to Maximize the Validity of Fitbit Device Data for Arthritis-Related Research Purposes
Background/Purpose: Health activity tracker devices (e.g. Fitbit) are increasingly used component of medical evaluation. However, the validity and suitability of the data from such devices…Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…Abstract Number: 1202 • 2018 ACR/ARHP Annual Meeting
Tenosynovial Aspiration By Ultrasound Guidance: Even Small Volumes Can Have a Big Impact
Background/Purpose: Rheumatologists commonly use synovial fluid analysis to help establish a diagnosis in patients with joint effusions. Although tenosynovial (TS) effusions are common in rheumatic…Abstract Number: 1205 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound and Conventional Radiography Evaluation of the Hip in Patients with Calcium Pyrophosphate Deposition Disease
Background/Purpose: Conventional radiography (CR) and, more recently, US play a key role in the diagnosis of CPPD. To date, only a very few studies have…Abstract Number: 1253 • 2018 ACR/ARHP Annual Meeting
Lipid Screening and Treatment Patterns Among Patients with Rheumatic Diseases
Background/Purpose: The importance of lipid management is well recognized in rheumatic diseases. In fact, annual cardiovascular risk assessment is especially recommended for individuals with rheumatoid…Abstract Number: 1286 • 2018 ACR/ARHP Annual Meeting
Pretreatment and Coadministration with Methotrexate Improved Durability of Pegloticase (Krystexxa) Response: A Prospective, Proof-of-Concept, Case Series
Background/Purpose: Pegloticase is a recombinant DNA-produced porcine-like uricase enzyme which metabolizes relatively insoluble urate to highly soluble allantoin. It is used in the treatment of…Abstract Number: 1292 • 2018 ACR/ARHP Annual Meeting
HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease
Background/Purpose: Allopurinol is the first line urate lowering drug used for treatment of gout. Its most feared side effect includes development of hypersensitivity drug reactions…Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »